AGGRAVATION BY PROPRANOLOL OF HYPERGLYCAEMIC EFFECT OF HYDROCHLOROTHIAZIDE IN TYPE II DIABETICS WITHOUT ALTERATION OF INSULIN SECRETION
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
14 hypertensive men with type II diabetes sequentially received, in random order, hydrochlorothiazide 50 mg twice a day, propranolol 80 mg twice a day, and both drugs in combination. The 3-week treatment periods were separated by a 1-week washout period. Hydrochlorothiazide significantly increased fasting glucose by 31% (p less than 0.05) and glycosylated haemoglobin (HbA1c) by 6.0% (p less than 0.10). A similar treatment period of propranolol 80 mg twice a day caused no significant increases. However, when both drugs were taken in combination, fasting glucose rose by 56% and HbA1c by 14.7% (p less than 0.01). The hyperglycaemic effect of hydrochlorothiazide and its potentiation by propranolol were independent of serum potassium and of endogenous insulin secretion as measured by urine C-peptide excretion. The combination of hydrochlorothiazide and propranolol thus seems to cause serious disturbances in glycaemic control in type II diabetics by mechanisms independent of insulin secretion.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many β-blockers (eg, metoprolol, atenolol) that effectively treat angina also have adverse metabolic effects”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [253]
In the citing paper
“β-Blockers reduce heart rate and myocardial contractility (thereby reducing myocardial oxygen demand), but this can induce compensatory peripheral vasoconstriction, which leads to increased insulin resistance and a more atherogenic lipid profile.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [253]
Citations
Cites
The Clinical Information Value of the Glycosylated Hemoglobin Assay
Nathan, D. M., Singer, D. E., Hurxthal, K., & Goodson, J. D. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402093100602 · Cited by 706
Hypertension, the Potassium Ion and Impaired Carbohydrate Tolerance
Conn, J. W. (1965) · New England Journal of Medicine · doi:10.1056/nejm196511182732106 · Cited by 329
Prevention of the Glucose Intolerance of Thiazide Diuretics by Maintenance of Body Potassium
Helderman, J. H., Elahi, D., Andersen, D. K., Raizes, G. S., Tobin, J. D., Shocken, D., & Andres, R. (1983) · Diabetes · doi:10.2337/diab.32.2.106 · Cited by 252
GLUCOSE INTOLERANCE DURING DIURETIC THERAPY
Amery, A., Bulpitt, C., Schaepdryver, A. D., Fagard, R., Hellemans, J., Mutsers, A., Berthaux, P., Deruyttere, M., Dollery, C., Forette, F., et al. (1978) · The Lancet · doi:10.1016/s0140-6736(78)90797-3 · Cited by 216
Adrenergic Modulation of Basal Insulin Secretion in Man
Robertson, R. P., & Porte, D. (1973) · Diabetes · doi:10.2337/diab.22.1.1 · Cited by 209
Hyperglycemia and Glycosuria Due to Thiazide Derivatives Administered in Diabetes Mellitus
Goldner, M. G., Zarowitz, H., & Akgun, S. (1960) · New England Journal of Medicine · doi:10.1056/nejm196002252620807 · Cited by 206
Robertson, R. P., & Porte, D. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107251 · Cited by 165
Glucose Tolerance and Insulin Responsiveness in Experimental Potassium Depletion
Sagild, U., Andersen, V., & Andreasen, P. B. (1961) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1961.tb07829.x · Cited by 148
Raskin, P., Pietri, A., Unger, R. H., & Shannon, W. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312223092504 · Cited by 141
MUGGEO, M., BAR, R. S., ROTH, J., KAHN, C. R., & GORDEN, P. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-48-1-17 · Cited by 132
Research works printed but not linked: 1
- 1981, Lancet, n, 539
Cited by
The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension
Kaplan, N. M. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.149.7.1514 · Cited by 1,516
Bakris, G. L., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Phillips, R. A., Raskin, P., Wright, J. T., Oakes, R., Lukas, M. A., et al. (2004) · JAMA · doi:10.1001/jama.292.18.2227 · Cited by 792
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Bakris, G. L., Fonseca, V., & Katholi, R. L. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.136 · Cited by 256
Gender-specific care of the patient with diabetes: review and recommendations
Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A., Rajan, S., Villagra, V., & Kosowski, M. (2006) · Gender Medicine · doi:10.1016/s1550-8579(06)80202-0 · Cited by 225
Metadata
- Authors
- Dornhorst, A., Powell, S., & Pensky, J.
- Affiliations
- Case Western Reserve University (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1985-01
- Volume
- 325
- Issue
- 8421
- Pages
- 123-126
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2019428374
- Cited by
- 100
- References
- 29
- Citations by year
- 2023: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 1
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hydrochlorothiazide, propranolol, type 2 diabetes, drug interactions, hyperglycemia, glycemic control, HbA1c, fasting blood glucose, insulin secretion, C-peptide, serum potassium, antihypertensive drugs
- MeSH terms
- Insulin Secretion, Aged, Blood Glucose, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Synergism, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hydrochlorothiazide, Hyperglycemia, Hypertension, Insulin, Male, Middle Aged, Potassium, Propranolol, Random Allocation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AGGRAVATION BY PROPRANOLOL OF HYPERGLYCAEMIC EFFECT OF HYDROCHLOROTHIAZIDE IN TYPE II DIABETICS WITHOUT ALTERATION OF INSULIN SECRETION. https://app.cochat.ai/papers/10.1016/s0140-6736(85)91900-2
- The paper
- Dornhorst, A., Powell, S., & Pensky, J. (1985). AGGRAVATION BY PROPRANOLOL OF HYPERGLYCAEMIC EFFECT OF HYDROCHLOROTHIAZIDE IN TYPE II DIABETICS WITHOUT ALTERATION OF INSULIN SECRETION. The Lancet. https://doi.org/10.1016/s0140-6736(85)91900-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.